Zacks Investment Research upgraded shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) from a sell rating to a hold rating in a research note published on Wednesday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
A number of other analysts have also commented on VBLT. HC Wainwright reaffirmed a buy rating and issued a $11.00 target price on shares of Vascular Biogenics in a research report on Tuesday, March 28th. ValuEngine downgraded Vascular Biogenics from a hold rating to a sell rating in a research note on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Vascular Biogenics has a consensus rating of Buy and a consensus target price of $12.90.
Vascular Biogenics (NASDAQ:VBLT) traded up 1.76% during midday trading on Wednesday, reaching $4.35. The company had a trading volume of 163,543 shares. The stock has a 50-day moving average price of $4.68 and a 200 day moving average price of $5.34. The company’s market capitalization is $117.05 million. Vascular Biogenics has a 12-month low of $3.80 and a 12-month high of $6.70.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. Equities analysts forecast that Vascular Biogenics will post ($0.82) EPS for the current year.
WARNING: “Vascular Biogenics Ltd. (VBLT) Upgraded at Zacks Investment Research” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/07/22/vascular-biogenics-ltd-vblt-upgraded-at-zacks-investment-research.html.
A hedge fund recently raised its stake in Vascular Biogenics stock. Menta Capital LLC raised its position in Vascular Biogenics Ltd. (NASDAQ:VBLT) by 5.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 121,935 shares of the biopharmaceutical company’s stock after buying an additional 6,200 shares during the period. Menta Capital LLC owned about 0.45% of Vascular Biogenics worth $671,000 as of its most recent filing with the SEC. Institutional investors own 14.02% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.